Lineage Cell Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.84M, a 42.7% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$22.7M, a 9.12% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$24.7M, a 9.83% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$22.5M, a 54.2% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$49.2M, a 86.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$22.7M -$3.84M +$2.87M +42.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$25.6M -$5.87M -$843K -16.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$24.8M -$6.66M -$19K -0.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$24.7M -$6.36M +$277K +4.17% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$25M -$6.71M -$1.45M -27.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$23.6M -$5.02M -$790K -18.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$22.8M -$6.64M -$246K -3.85% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$22.5M -$6.64M +$21.6M +76.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$44.1M -$5.25M +$1.59M +23.3% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-07
Q2 2022 -$45.7M -$4.23M +$2.85M +40.2% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-07
Q1 2022 -$48.6M -$6.4M +$654K +9.28% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-07
Q4 2021 -$49.2M -$28.2M -$22.4M -380% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$26.9M -$6.84M -$118K -1.76% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-09
Q2 2021 -$26.7M -$7.08M -$678K -10.6% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-09
Q1 2021 -$26.1M -$7.05M +$388K +5.22% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-09
Q4 2020 -$26.4M -$5.88M +$990K +14.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$27.4M -$6.73M +$1.7M +20.2% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 -$29.1M -$6.4M +$4.42M +40.8% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 -$33.6M -$7.44M +$5.32M +41.7% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q4 2019 -$38.9M -$6.87M +$3.24M +32% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$42.1M -$8.42M +$1.94M +18.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-11
Q2 2019 -$44M -$10.8M -$1.68M -18.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-11
Q1 2019 -$42.4M -$12.8M -$574K -4.71% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-11
Q4 2018 -$41.8M -$10.1M -$544K -5.69% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$41.3M -$10.4M -$844K -8.87% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$40.4M -$9.14M -$580K -6.77% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$39.8M -$12.2M -$925K -8.21% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$38.9M -$9.56M +$1.69M +15% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$40.6M -$9.51M +$42K +0.44% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$40.6M -$8.56M +$5.84M +40.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$46.5M -$11.3M +$12.5M +52.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$59M -$11.3M +$10.5M +48.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$69.4M -$9.56M +$7.55M +44.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$77M -$14.4M -$907K -6.72% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$76.1M -$23.8M -$10.3M -76% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$65.8M -$21.7M -$7.3M -50.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$58.5M -$17.1M -$4.97M -40.9% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$53.5M -$13.5M -$434K -3.32% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$53.1M -$13.5M -$2.36M -21.2% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$50.7M -$14.4M +$14.9M +50.8% Oct 2, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$65.6M -$12.1M -$1.94M -19% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$63.7M -$13.1M -$4.95M -60.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$58.7M -$11.1M -$2.76M -32.9% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
Q4 2013 -$56M -$29.3M -$22.2M -315% Sep 29, 2013 Dec 31, 2013 10-K 2015-03-11
Q3 2013 -$33.8M -$10.2M -$4.26M -71.6% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-11
Q2 2013 -$29.5M -$8.12M -$2.04M -33.5% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-11
Q1 2013 -$27.5M -$8.38M -$2.46M -41.7% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-11
Q4 2012 -$25M -$7.06M -$1.61M -29.6% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$23.4M -$5.95M -$1.71M -40.5% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$21.7M -$6.08M -$1.1M -22.1% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$20.6M -$5.92M -$1.89M -46.9% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
Q4 2011 -$18.7M -$5.45M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$4.23M -$1.77M -72.2% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$4.98M -$2.67M -115% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$4.03M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$2.46M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$2.32M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.